Author Index Volume 5 (2016)

The issue number is given in front of the pagination

Agrawal, S., see Berggren, K.L. (1) 53–63
Andelic, N., see van Walsem, M.R. (3) 261–270
Anderson, K.E., S. Eberly, M. Groves, E. Kayson, K. Marder, A.B. Young, I. Shoulson and PHAROS Investigators, Risk Factors for Suicidal Ideation in People at Risk for Huntington’s Disease (4) 389–394
Andrews, S.C., see Philpott, A.L. (2) 175–183
Aronin, N., see Keeler, A.M. (3) 239–248
Aronin, N., see Liu, W. (1) 33–38
Aronin, N., see Vodicka, P. (2) 163–174
Aronin, N., see Vodicka, P. (3) 249–260
Baake, V., E.P. Hart, R. Bos and R.A.C. Roos, Participants at the Leiden Site of the REGISTRY Study: A Demographic Approach (1) 83–90
Bates, G.P., see Osmand, A.P. (4) 343–346
Bichell, T.J., see Osmand, A.P. (4) 343–346
Biglan, K.M., see Andrzejewski, K.L. (2) 199–206
Bjelik, A., see Billes, V. (2) 133–147
Bos, R., see Baake, V. (1) 83–90
Bouwens, J.A., E. van Duijn, C.M. Cobbaert, R.A.C. Roos, R.C. van der Mast and E.J. Giltau, Plasma Cytokine Levels in Relation to Neuropsychiatric Symptoms and Cognitive Dysfunction in Huntington’s disease (4) 369–377
Bowman, A.B., see Osmand, A.P. (4) 343–346
Braisch, U., S. Martinez-Horta, M. MacDonald and M. Orth, Important but not Enough – Information about HD Related Topics and Peer and Professional Support for Young Adults from HD Families (4) 379–387
Brooks, S.P., see Yhnell, E. (2) 149–161
Byrne, L.M. and E.J. Wild, Cerebrospinal Fluid Biomarkers for Huntington’s Disease (1) 1–13
Cai, H., see Andrzejewski, K.L. (2) 199–206
Cepeda, C., see Chen, J.Y. (1) 65–81
Chase, K., see Keeler, A.M. (3) 239–248
Chase, K., see Vodicka, P. (2) 163–174
Chase, K., see Vodicka, P. (3) 249–260
Chase, K.O., see Liu, W. (1) 33–38
Chen, J.Y., C. Tran, L. Hwang, G. Deng, M.E. Jung, K.F. Faull, M.S. Levine and C. Cepeda, Partial Amelioration of Peripheral and Central Symptoms of Huntington’s Disease via Modulation of Lipid Metabolism (1) 65–81
Chopra, V., L. Quinti, P. Khanna, P. Paganetti, R. Kuhn, A.B. Young, A.G. Kazantzsev and S. Hersch, LBH589, A Hydroxamic Acid-Derived HDAC Inhibitor, is Neuroprotective in Mouse Models of Huntington’s Disease (4) 347–355
Churchyard, A., see Philpott, A.L. (2) 175–183
Cobbaert, C.M., see Bouwens, J.A. (4) 369–377
Corey-Bloom, J., S. Gluhm, A. Herndon, A.S. Haque, S. Park and P.E. Gilbert, Benton Judgment of Line Orientation (JoLO) Test: A Brief and Useful Measure for Assessing Visuospatial Abilities in Manifest, but not Premanifest, Huntington’s Disease (1) 91–96
Culver, B.P., J. DeClercq, I. Dolgalev, M.S. Yu, B. Ma, A. Heguy and N. Tanese, Huntington’s Disease Protein Huntingtin Associates with its own mRNA (1) 39–51
D’Souza, G.X. and H.J. Waldvogel, Targeting the Cholinergic System to Develop a Novel Therapy for Huntington’s Disease (4) 333–342
Danielson, E., see Keeler, A.M. (3) 239–248
De Soriano, I., see Downing, N.R. (4) 357–368
De Clercq, J., see Culver, B.P. (1) 39–51
Deng, G., see Chen, J.Y. (1) 65–81
DiFiglia, M., see Keeler, A.M. (3) 239–248
DiFiglia, M., see Liu, W. (1) 33–38
DiFiglia, M., see Vodicka, P. (2) 163–174
DiFiglia, M., see Vodicka, P. (3) 249–260
Dolgalev, I., see Culver, B.P. (1) 39–51
Dorsey, E.R., see Andrzejewski, K.L. (2) 199–206
Dowling, A.V., see Andrzejewski, K.L. (2) 199–206
Downing, N.R., S. Lourens, I. De Soriano, J.D.
Long and J.S. Paulsen for the PREDICT-HD
Investigators and Coordinators of the Huntington
Study Group, Phenotype Characterization of HD
Intermediate Alleles in PREDICT-HD (4) 357–
368
Dudenhoeffer, M., see Berggren, K.L. (1) 53–63
Dunnett, S.B., see Yhnell, E. (2) 149–161
Eberly, S., see Anderson, K.E. (4) 389–394
Edmondson, M., see Frich, J.C. (2) 207–213
Erdös, A., see Billes, V. (2) 133–147
Faull, K.F., see Chen, J.Y. (1) 65–81
Faull, R.L.M., see Geraerts, F.C.A. (3) 297–301
Felong, T.J., see Andrzejewski, K.L. (2) 199–206
Fisher, C.A., see Moorhouse, B. (1) 15–17
Fisher, F., see Philpott, A.L. (2) 175–183
Fox, J.A., see Berggren, K.L. (1) 53–63
Fox, J.H., see Berggren, K.L. (1) 53–63
Frich, J.C., D. Rae, R. Roxburgh, Z.H. Miedzybrodzka,
M. Edmondson, E.B. Pope, L.V. Goodman, M.S.
Haddad, J. Giuliano, E.C. Nelson, M. Guttman
and M. Nance, Health Care Delivery Practices
in Huntington’s Disease Specialty Clinics: An
International Survey (2) 207–213
Frich, J.C., see van Walsem, M.R. (3) 261–270
Garner, B., see Kreilaus, F. (3) 285–296
Geraerts, F.C.A., R.G. Snell, R.L.M. Faull, L. Williams,
J.C. Jacobsen and S.J. Reid, Comparison of
Huntington’s disease CAG Repeat Length
Stability in Human Motor Cortex and Cingulate
Gyrus (3) 297–301
Gilbert, P.E., see Corey-Bloom, J. (1) 91–96
Giltay, E.J., see Bouwens, J.A. (4) 369–377
Giltay, E.J., see Hubers, A.A.M. (2) 185–198
Giuliano, J., see Frich, J.C. (2) 207–213
Gluhm, S., see Corey-Bloom, J. (1) 91–96
Goodman, L.V., see Frich, J.C. (2) 207–213
Groves, M., see Anderson, K.E. (4) 389–394
Gulya, K., see Billes, V. (2) 133–147
Gulyás, B., see Billes, V. (2) 133–147
Gutman, B., see Frich, J.C. (2) 207–213
Gwin, J.T., see Andrzejewski, K.L. (2) 199–206
Haddad, M.S., see Frich, J.C. (2) 207–213
Hamming, A., see Hubers, A.A.M. (2) 185–198
Hannan, A.J., see Kreilaus, F. (3) 285–296
Haque, A.S., see Corey-Bloom, J. (1) 91–96
Harris, D.A., see Andrzejewski, K.L. (2) 199–206
Hart, E.P., see Baake, V. (1) 83–90
Heguy, A., see Culver, B.P. (1) 39–51
Herndon, A., see Corey-Bloom, J. (1) 91–96
Hersch, S., see Chopra, V. (4) 347–355
Hotzi, B., see Billes, V. (2) 133–147
Howe, E.I., see van Walsem, M.R. (3) 261–270
Hubers, A.A.M., A. Hamming, E.J. Giltay, M. von
Faber, R.A.C. Roos, R.C. van der Mast and E.
van Duijn, Suicidality in Huntington’s Disease: A
Qualitative Study on Coping Styles and Support
Strategies (2) 185–198
Hwang, L., see Chen, J.Y. (1) 65–81
Induced Pluripotent Stem Cells in Huntington’s
Disease Research: Progress and Opportunity (2)
99–131
Iuliano, M., see Vodicka, P. (2) 163–174
Iuliano, M., see Vodicka, P. (3) 249–260
Jacobson, J.C., see Geraerts, F.C.A. (3) 297–301
Jenner, A.M., see Kreilaus, F. (3) 285–296
Jung, M.E., see Chen, J.Y. (1) 65–81
Kayson, E., see Anderson, K.E. (4) 389–394
Kazantzsev, A.G., see Chopra, V. (4) 347–355
Keeler, A.M., E. Sapp, K. Chase, E. Sottosanti, E.
Danielson, E. Pfister, L. Stoica, M. DiFiglia, N.
Armon and M. Sena-Esteves, Cellular Analysis
of Silencing the Huntington’s Disease Gene Us-
ing AAV9 Mediated Delivery of Artificial Micro
RNA into the Striatum of Q140/Q140 Mice (3)
239–248
Kegel-Gleason, K.B., see Tousley, A. (2) 99–131
Kegel-Gleason, K.B., see Vodicka, P. (2) 163–174
Kegel-Gleason, K.B., see Vodicka, P. (3) 249–260
Kennington, L.A., see Liu, W. (1) 33–38
Khanna, P., see Chopra, V. (4) 347–355
Kogan, J., see Simpson, J.A. (4) 395–403
Komlós, M., see Billes, V. (2) 133–147
Kovács, T., see Billes, V. (2) 133–147
Kuhn, R., see Chopra, V. (4) 347–355
Kumar, A. and R.R. Ratan, Oxidative Stress and Huntington’s Disease: The Good, The Bad, and The Ugly (3) 217–237
Legradi, A., see Billes, V. (2) 133–147
Levine, M.S., see Chen, J.Y. (1) 65–81
Little, M.A., see Andrzejewski, K.L. (2) 199–206
Long, J.D., see Downing, N.R. (4) 357–368
Lourens, S., see Downing, N.R. (4) 357–368
Lovecky, D., see Simpson, J.A. (4) 395–403
Lu, B., see Vodicka, P. (2) 163–174
Lu, Z., see Berggren, K.L. (1) 53–63
Ma, B., see Culver, B.P. (1) 39–51
MacDonald, M., see Braisch, U. (4) 379–387
Manzéger, A., see Billes, V. (2) 133–147
Marder, K., see Anderson, K.E. (4) 389–394
Martinez-Horta, S., see Braisch, U. (4) 379–387
Miedzybrodzka, Z.H., see Frich, J.C. (2) 207–213
Moorhouse, B. and C.A. Fisher, Long-Term use of Modified Diets in Huntington’s Disease: A Descriptive Clinical Practice Analysis on Improving Dietary Enjoyment (1) 15–17
Morton, A.J., see Sawiak, S.J. (3) 271–283
Morton, A.J., see Skillings, E.A. (1) 19–32
Mueller, C., see Liu, W. (1) 33–38
Nance, M., see Frich, J.C. (2) 207–213
Nelson, E.C., see Frich, J.C. (2) 207–213
Neonatal Iron Supplementation Induces Striatal Atrophy in Female YAC128 Huntington’s Disease Mice (1) 53–63
Orth, M., see Braisch, U. (4) 379–387
Pádár, Z., see Billes, V. (2) 133–147
Paganetti, P., see Chopra, V. (4) 347–355
Park, S., see Corey-Bloom, J. (1) 91–96
Paulsen, J.S., see Downing, N.R. (4) 357–368
Pfister, E., see Keeler, A.M. (3) 239–248
Pfister, E.L., see Liu, W. (1) 33–38
Pope, E.B., see Frich, J.C. (2) 207–213
Quinti, L., see Chopra, V. (4) 347–355
Rae, D., see Frich, J.C. (2) 207–213
Rangel-Barajas, C. and G.V. Rebec, Dysregulation of Corticostratial Connectivity in Huntington’s Disease: A Role for Dopamine Modulation (4) 303–331
Ratan, R.R., see Kumar, A. (3) 217–237
Rebec, G.V., see Rangel-Barajas, C. (4) 303–331
Reid, S.J., see Geraerts, F.C.A. (3) 297–301
Reilmann, R., see Andrzejewski, K.L. (2) 199–206
Roos, R.A.C., see Baake, V. (1) 83–90
Roos, R.A.C., see Bouwens, J.A. (4) 369–377
Roos, R.A.C., see Hubers, A.A.M. (2) 185–198
Roxburgh, R., see Frich, J.C. (2) 207–213
Sapp, E., see Keeler, A.M. (3) 239–248
Sapp, E., see Vodicka, P. (2) 163–174
Sapp, E., see Vodicka, P. (3) 249–260
Sawiak, S.J., N.I. Wood and A.J. Morton, Similar Progression of Morphological and Metabolic Phenotype in R6/2 Mice with Different CAG Repeats Revealed by In Vivo Magnetic Resonance Imaging and Spectroscopy (3) 271–283
Sena-Esteves, M., see Keeler, A.M. (3) 239–248
Sena-Esteves, M., see Vodicka, P. (2) 163–174
Sena-Esteves, M., see Vodicka, P. (3) 249–260
Shoulson, I., see Anderson, K.E. (4) 389–394
Skillings, E.A. and A.J. Morton, Delayed Onset and Reduced Cognitive Deficits through Pre-Conditioning with 3-Nitropropionic Acid is Dependent on Sex and CAG Repeat Length in the R6/2 Mouse Model of Huntington’s Disease (1) 19–32
Snell, R.G., see Geraerts, F.C.A. (3) 297–301
Sottosanti, E., see Keeler, A.M. (3) 239–248
Sprio, A.S., see Kreilaus, F. (3) 285–296
Staios, M., see Philpott, A.L. (2) 175–183
Stamler, D., see Andrzejewski, K.L. (2) 199–206
Stoica, L., see Keeler, A.M. (3) 239–248
Tagscherer, K., see Billes, V. (2) 133–147
Tanese, N., see Culver, B.P. (1) 39–51
Tarnóci, A., see Billes, V. (2) 133–147
Tousley, A. and K.B. Kegel-Gleason
Tousley, A., see Vodicka, P. (3) 249–260
Tran, C., see Chen, J.Y. (1) 65–81
Valentine, D.T., see Vodicka, P. (2) 163–174
Valentine, D.T., see Vodicka, P. (3) 249–260
van der Mast, R.C., see Bouwens, J.A. (4) 369–377
van der Mast, R.C., see Hubers, A.A.M. (2) 185–198
van Duijn, E., see Bouwens, J.A. (4) 369–377
van Duijn, E., see Hubers, A.A.M. (2) 185–198
van Walsem, M.R., E.I. Howe, J.C. Frich and N. Andelic, Assistive Technology for Cognition and Health-related Quality of Life in Huntington’s Disease (3) 261–270
Vellai, T., see Billes, V. (2) 133–147
von Faber, M., see Hubers, A.A.M. (2) 185–198
Waldvogel, H.J., see D’Souza, G.X. (4) 333–342
Wild, E.I., see Byrne, L.M. (1) 1–13
Williams, L., see Geraerts, F.C.A. (3) 297–301
Wong, C., see Andrzejewski, K.L. (2) 199–206
Wood, N.I., see Sawiak, S.J. (3) 271–283
Yhnell, E., S.B. Dunnett and S.P. Brooks, A Longitudinal Motor Characterisation of the HdhQ111 Mouse Model of Huntington’s Disease (2) 149–161
Yohrling, G.J., see Simpson, J.A. (4) 395–403
Young, A.B., see Anderson, K.E. (4) 389–394
Young, A.B., see Chopra, V. (4) 347–355
Yu, M.S., see Culver, B.P. (1) 39–51